Guidelines on the use of intravenous immune globulin for neurologic conditions in Canada.
Recommendations for use of IVIG were made for 14 conditions, including acute disseminated encephalomyelitis, chronic inflammatory demyelinating polyneuropathy, dermatomyositis, diabetic neuropathy, Guillain-Barre syndrome, Lambert-Eaton myasthenic syndrome, multifocal motor neuropathy, multiple sclerosis, myasthenia gravis, opsoclonus-myoclonus, pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections, polymyositis, Rasmussen’s encephalitis, and stiff person syndrome; IVIG was not recommended for 8 conditions including adrenoleukodystrophy, amyotropic lateral sclerosis, autism, critical illness polyneuropathy, inclusion body, myositis, intractable childhood epilepsy, paraproteinemic neuropathy (IgM variant), and POEMS syndrome.
See the following link
http://ivig.blogspot.com/2007/04/new-guidelines-on-use-of-intravenous.html
You must be logged in to reply to this topic.
© Copyright GBS|CIDP Foundation International Forums.
Use of this Web site constitutes acceptance of our Terms of Use and Privacy Policy.
GBS|CIDP Foundation International is a 501(c)3 tax-exempt organization.
Cookie | Duration | Description |
---|---|---|
CONSENT | 16 years 6 months 14 days 2 hours 6 minutes | No description |
cookielawinfo-checkbox-functional | 1 year | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
cookielawinfo-checkbox-others | 1 year | No description |